Two studies, one carried out by our team, revealed that NF-κB activation was increased in response to Cab in pancreatic cancer and mCRPC cells, and this activation was consistent with the pro-apoptotic activity of the drug.23,24 Moreover, Cab efficacy increased when combined with NF-κB inhibitors in advanced pancreatic cancer.23 Interestingly, we showed for the first time that Cab inhibited p-NF-κB in LNCaP cells, on which more apoptotic effect was detected. Here, NFKB1 is linked to familial pancreatic carcinoma.